

# Results announcement

(for Equity Security issuer/Equity and Debt Security issuer)

Updated as at 8 May 2019



Results for announcement to the market		
AFT Pharmaceuticals Limited		
Reporting Period	6 months to September 30 2019	
Previous Reporting Period	6 months to September 30 2018	
Currency	NZ\$	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$46,946	Up 22%
Total Revenue	\$46,946	Up 22%
Net profit/(loss) from continuing operations	\$13,691	Up ++%
Total net profit/(loss)	\$13,691	Up ++%
Interim/Final Dividend		
Amount per Quoted Equity Security	Unlisted redeemable preference shares NZ 3.5c	
Imputed amount per Quoted Equity Security	Unlisted redeemable preference shares NZ 0.0c	
Record Date	14 September 2019	
Dividend Payment Date	30 September 2019	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$(0.09)	\$(0.04)
A brief explanation of any of the figures above necessary to enable the figures to be understood	<p>Accompanying this announcement are the Group's unaudited consolidated financial statements for the six months ended September 30 2019. These financial statements and the half year results commentary dated November 21 2019 provide the balance of information requirements in accordance with NZX Listing Rule 3.5 and Appendix 2.</p> <p>Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals Limited confirms that it continues to comply with the rules of its home exchange (NZX Main Board).</p> <p>The unlisted Redeemable preference shares issued on March 24 2017 attract a dividend rate of 9.4% per annum, or 25.8 cents per share per annum. For the 30 June 2019 quarter end no dividends were paid. For the 30 September 2019 quarter end 50% of the dividend was paid in cash and included in the above table. The remaining 50% of dividends net of withholding taxes for the 30 September 2019 quarter</p>	

	<p>end together with all of the dividends net of withholding taxes for the 30 June 2019 quarter end have been accumulated in the Redeemable Preference Share Reserve.</p> <p>No dividends have been paid on ordinary shares.</p>
<b>Authority for this announcement</b>	
Name of person authorised to make this announcement	Malcolm Tubby
Contact person for this announcement	Malcolm Tubby, Chief Financial Officer, AFT Pharmaceuticals Ltd
Contact phone number	+64 9 488 0232
Contact email address	malcolm@aftpharm.com
Date of release through MAP	21 November 2019

Audited financial statements accompany this announcement.